Oculis Holding AG (OCS) Total Current Liabilities (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Total Current Liabilities of $56.0 million for Q1 2026, up 27.65% year-over-year from $43.9 million in Q1 2025, and up 21.83% quarter-over-quarter from $46.0 million in Q4 2025.
Oculis Holding AG (OCS) Total Current Liabilities (2021 - 2026) Analysis & Trends
Oculis Holding AG's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $56.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 27.65% year-over-year to $56.0 million; the TTM figure through Mar 2026 stood at $56.0 million (up 27.65% YoY), while the FY2025 annual figure was $44.3 million, down 11.85% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $56.0 million, up from $46.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $56.0 million in Q1 2026, with the low at $12.5 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $32.0 million (2024), against an average of $33.8 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 183.23% in 2022, then declined 8.95% in 2025.
- Oculis Holding AG's Total Current Liabilities stood at $12.5 million in 2022, then jumped by 72.47% to $21.5 million in 2023, then soared by 134.65% to $50.5 million in 2024, then fell by 8.95% to $46.0 million in 2025, then advanced by 21.83% to $56.0 million in 2026.
- Business Quant data shows OCS's Total Current Liabilities at $56.0 million in Q1 2026, $46.0 million in Q4 2025, and $42.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 35.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.33 Mn |
| Mar 31, 2026 | 56.01 Mn |
| Dec 31, 2025 | 45.98 Mn |
| Sep 30, 2025 | 42.16 Mn |
| Jun 30, 2025 | 44.14 Mn |
| Mar 31, 2025 | 43.88 Mn |
| Dec 31, 2024 | 50.50 Mn |
| Sep 30, 2024 | 31.99 Mn |
| Jun 30, 2024 | 26.13 Mn |
| Mar 31, 2024 | 20.80 Mn |
| Dec 31, 2023 | 21.52 Mn |
| Sep 30, 2023 | 25.08 Mn |
| Jun 30, 2023 | 18.69 Mn |
| Dec 31, 2022 | 12.48 Mn |
| Dec 31, 2021 | 4.41 Mn |